![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, August 13, 2023 1:15:35 PM
ANAVEX 3-71 Meets Primary, Secondary End Points in Phase 1 Study
Jan 12, 2022 Abby Reinhard
A phase 1 study of ANAVEX 3-71 (NCT04442945), an oral small molecule agonist of both SIGMAR1 and CHRM1 (Cholinergic Receptor Muscarinic M1), met its primary safety end point, as well as its secondary end point, Anavex Life Sciences recently announced. The drug is in development for treatment of neurodegenerative diseases and has previously been granted orphan drug designation by the FDA for treatment of frontotemporal dementia (FTD).1
The double-blind, randomized, placebo-controlled trial evaluated the safety, efficacy, and pharmacokinetics (PK) of oral escalating doses of ANAVEX 3-71 in evaluating in healthy patients. Investigators concluded that the treatment, previously known as AF710B, was well tolerated in all cohorts receiving single doses, ranging from 5-200 mg daily. No serious adverse events or significant lab abnormalities were reported. The treatment showed linear PK, which was also dose proportional up to 160 mg and was unaffected by gender. Food was not found to have an effect the bioavailability of the treatment.
“We are pleased with the phase 1 trial results for ANAVEX 3-71 and are eager to advance ANAVEX 3-71 into phase 2,” Christopher U. Missling, PhD, president and CEO, Anavex, said in a statement.1 “These encouraging results provide a proof of concept of our SIGMAR1 product platform and helps validate Anavex’s approach to CNS target selection and drug discovery and increases Anavex’s confidence in the potential of our precision medicine technology to address serious neurodegenerative diseases.”
Meeting its secondary end point, the study also characterized the effect of ANAVEX 3-71 on electrocardiogram parameters, which were not clinically significant in any subject. Across all dose groups, participant QT interval corrected for heart rate by Fredericia’s cube root formula measures were normal, with no differences observed between treatment and placebo groups.
The study included a total of 42 men and women between the age of 18-35 years who were given up to 4 single escalating doses of ANAVEX 3-71 or placebo, administered orally over a 30-day period. Participants were divided into 3 cohorts, the first receiving 5-50 mg oral doses of ANAVEX 3-71, the second receiving 55-200 mg, and the third receiving placebo. Participants were required to be non-smokers, have a body mass index of 19-28 kg/m2, have a body weight of 60-120 kg, and be in generally good health at the time of screening. Women were required to be of non-childbearing potential or using contraception.
Based on the positive topline results from phase 1, Anavex plans to evaluate the treatment in a biomarker-driven clinical development dementia program for the treatment of FTD, as well as schizophrenias and Alzheimer disease. The study will be a quasi-basket trial and is anticipated to being in 2022 and will evaluate longitudinal effects of the treatment.
“In addition to biomarkers…we would like to look at the neurofilament light change, NFL,” Edward Hammond, MD, MPH, PhD, chief medical officer, Avanex Life Sciences, said during a webcast conference call discussing the topline results.2 “We will also look at plasma and serum concentrations of glutamate and other related amino acids. We are looking at TDP43, GRP78 concentrations as well, so it is quite a comprehensive biomarker strategy that will be able to demonstrate the effect of 3-71 on these pathologies, in order to give confidence going into further development.”
REFERENCES
1. Anavex Life Sciences reports positive results from phase 1 clinical trial. Avanex Life Sciences. January 10, 2022. Accessed January 11, 2022. https://www.anavex.com/post/anavex-life-sciences-reports-positive-results-from-phase-1-clinical-trial-of-anavex-3-71
2. Anavex 3-71 Phase 1 Top Line Data Conference Call. Anavex website. January 10, 2022. Accessed January 11, 2022. https://www.anavex.com/anavex3-71phase1toplinedataconferencecall
https://www.neurologylive.com/view/anavex-3-71-meets-primary-secondary-end-points-phase-1-study
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM